04.04.2017 • TopicsDr. Gerd BergmannNordmannNRC

‘A Blessing and a Curse’

Dr. Gerd Bergmann, managing director, Nordmann, Rassmann (NRC)
Dr. Gerd Bergmann, managing director, Nordmann, Rassmann (NRC)

“Digitalization is both a blessing and a curse. On the one hand, digitalized sales channels will increase price and market transparency and therefore adversely affect sales prices and margins. On the other hand, the advancing digitalization creates unprecedented opportunities for new business models, new ways of selling and new channels to the market. Certainly digitalization of the supply chain across all levels will fundamentally change the rather conservative order methods of our current customers — via telephone, fax, etc.

In order to meet the challenges of the digital transformation and reap maximum benefits, we created a cross-division internal working group. Finally, we do not perceive the market developments associated with digitalization as a threat but rather as a challenge and opportunity.“

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.